soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction (Semaglutide triaL) in individuals with SOUL trial: Oral semaglutide demonstrates – Cardio-kidney-metabolic protective effects of semaglutide – Forecasting Trial Milestones: A Predictive

Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, et al

To be clear, GLP-1s are not FDA-approved for treating these conditions right now, but if more research proves they are safe and effective, they could receive formal approval for these uses (or others) in the future

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1) medication prescribed to manage Type 2 diabetes, reduce the risk of cardiovascular events like heart attacks, and assist with chronic weight management

As GLP-1s enhance gut motility and enzyme secretion, some patients may experience diarrhea

Neurodevelopmental problems at 18 months among children exposed to paracetamol in utero: a propensity score matched cohort study

Allegations against Novo Nordisk: The woman accuses Novo Nordisk of failing to adequately warn about the risk of gastroparesis associated with the drug, sparking concerns about transparency in drug packaging